Benefits of high-dose, high-frequency interferon beta-1a in relapsing-remitting multiple sclerosis are sustained to 16 months: Final comparative results of the EVIDENCE trial

Hillel Panitch; Douglas Goodin; Gordon Francis; Peter Chang; Patricia Coyle; Paul O'Connor; David Li; Brian Weinshenker

doi:10.1016/j.jns.2005.08.003

Benefits of high-dose, high-frequency interferon beta-1a in relapsing-remitting multiple sclerosis are sustained to 16 months: Final comparative results of the EVIDENCE trial

Hillel Panitch, Douglas Goodin, Gordon Francis, Peter Chang, Patricia Coyle, Paul O'Connor, David Li, Brian Weinshenker

Neurology

Research output: Contribution to journal › Article › peer-review

80 Scopus citations

Abstract

The EVIDENCE trial demonstrated that interferon (IFN) beta-1a, 44 mcg subcutaneously (sc) three times weekly (tiw) (Rebif®), was significantly more effective than IFN beta-1a, 30 mcg intramuscularly (im) once weekly (qw) (Avonex®), in reducing relapses and magnetic resonance imaging (MRI) activity in patients with relapsing-remitting multiple sclerosis at both 24 and 48 weeks of therapy. We now present final comparative data on these patients, showing that the superior efficacy of IFN beta-1a, 44 mcg sc tiw, for relapse measures and MRI activity, compared with IFN beta-1a, 30 mcg im qw, was sustained for at least 16 months. The development of antibodies to IFN was associated with reduced efficacy on MRI measures and fewer IFN-related adverse events, but did not have an impact on relapse outcomes.

Original language	English (US)
Pages (from-to)	67-74
Number of pages	8
Journal	Journal of the neurological sciences
Volume	239
Issue number	1
DOIs	https://doi.org/10.1016/j.jns.2005.08.003
State	Published - Dec 15 2005

Keywords

Comparative study
Interferon beta
Magnetic resonance imaging (MRI)
Multiple sclerosis (MS)
Neutralizing antibodies

ASJC Scopus subject areas

Neurology
Clinical Neurology

Access to Document

10.1016/j.jns.2005.08.003

Cite this

Panitch, H., Goodin, D., Francis, G., Chang, P., Coyle, P., O'Connor, P., Li, D., & Weinshenker, B. (2005). Benefits of high-dose, high-frequency interferon beta-1a in relapsing-remitting multiple sclerosis are sustained to 16 months: Final comparative results of the EVIDENCE trial. Journal of the neurological sciences, 239(1), 67-74. https://doi.org/10.1016/j.jns.2005.08.003

Benefits of high-dose, high-frequency interferon beta-1a in relapsing-remitting multiple sclerosis are sustained to 16 months: Final comparative results of the EVIDENCE trial. / Panitch, Hillel; Goodin, Douglas; Francis, Gordon et al.
In: Journal of the neurological sciences, Vol. 239, No. 1, 15.12.2005, p. 67-74.

Research output: Contribution to journal › Article › peer-review

Panitch, H, Goodin, D, Francis, G, Chang, P, Coyle, P, O'Connor, P, Li, D & Weinshenker, B 2005, 'Benefits of high-dose, high-frequency interferon beta-1a in relapsing-remitting multiple sclerosis are sustained to 16 months: Final comparative results of the EVIDENCE trial', Journal of the neurological sciences, vol. 239, no. 1, pp. 67-74. https://doi.org/10.1016/j.jns.2005.08.003

@article{c60f9116673d4c11a8984ee12e6220bc,

title = "Benefits of high-dose, high-frequency interferon beta-1a in relapsing-remitting multiple sclerosis are sustained to 16 months: Final comparative results of the EVIDENCE trial",

abstract = "The EVIDENCE trial demonstrated that interferon (IFN) beta-1a, 44 mcg subcutaneously (sc) three times weekly (tiw) (Rebif{\textregistered}), was significantly more effective than IFN beta-1a, 30 mcg intramuscularly (im) once weekly (qw) (Avonex{\textregistered}), in reducing relapses and magnetic resonance imaging (MRI) activity in patients with relapsing-remitting multiple sclerosis at both 24 and 48 weeks of therapy. We now present final comparative data on these patients, showing that the superior efficacy of IFN beta-1a, 44 mcg sc tiw, for relapse measures and MRI activity, compared with IFN beta-1a, 30 mcg im qw, was sustained for at least 16 months. The development of antibodies to IFN was associated with reduced efficacy on MRI measures and fewer IFN-related adverse events, but did not have an impact on relapse outcomes.",

keywords = "Comparative study, Interferon beta, Magnetic resonance imaging (MRI), Multiple sclerosis (MS), Neutralizing antibodies",

author = "Hillel Panitch and Douglas Goodin and Gordon Francis and Peter Chang and Patricia Coyle and Paul O'Connor and David Li and Brian Weinshenker",

year = "2005",

month = dec,

day = "15",

doi = "10.1016/j.jns.2005.08.003",

language = "English (US)",

volume = "239",

pages = "67--74",

journal = "Journal of the neurological sciences",

issn = "0022-510X",

publisher = "Elsevier",

number = "1",

}

TY - JOUR

T1 - Benefits of high-dose, high-frequency interferon beta-1a in relapsing-remitting multiple sclerosis are sustained to 16 months

T2 - Final comparative results of the EVIDENCE trial

AU - Panitch, Hillel

AU - Goodin, Douglas

AU - Francis, Gordon

AU - Chang, Peter

AU - Coyle, Patricia

AU - O'Connor, Paul

AU - Li, David

AU - Weinshenker, Brian

PY - 2005/12/15

Y1 - 2005/12/15

N2 - The EVIDENCE trial demonstrated that interferon (IFN) beta-1a, 44 mcg subcutaneously (sc) three times weekly (tiw) (Rebif®), was significantly more effective than IFN beta-1a, 30 mcg intramuscularly (im) once weekly (qw) (Avonex®), in reducing relapses and magnetic resonance imaging (MRI) activity in patients with relapsing-remitting multiple sclerosis at both 24 and 48 weeks of therapy. We now present final comparative data on these patients, showing that the superior efficacy of IFN beta-1a, 44 mcg sc tiw, for relapse measures and MRI activity, compared with IFN beta-1a, 30 mcg im qw, was sustained for at least 16 months. The development of antibodies to IFN was associated with reduced efficacy on MRI measures and fewer IFN-related adverse events, but did not have an impact on relapse outcomes.

AB - The EVIDENCE trial demonstrated that interferon (IFN) beta-1a, 44 mcg subcutaneously (sc) three times weekly (tiw) (Rebif®), was significantly more effective than IFN beta-1a, 30 mcg intramuscularly (im) once weekly (qw) (Avonex®), in reducing relapses and magnetic resonance imaging (MRI) activity in patients with relapsing-remitting multiple sclerosis at both 24 and 48 weeks of therapy. We now present final comparative data on these patients, showing that the superior efficacy of IFN beta-1a, 44 mcg sc tiw, for relapse measures and MRI activity, compared with IFN beta-1a, 30 mcg im qw, was sustained for at least 16 months. The development of antibodies to IFN was associated with reduced efficacy on MRI measures and fewer IFN-related adverse events, but did not have an impact on relapse outcomes.

KW - Comparative study

KW - Interferon beta

KW - Magnetic resonance imaging (MRI)

KW - Multiple sclerosis (MS)

KW - Neutralizing antibodies

UR - http://www.scopus.com/inward/record.url?scp=27744516986&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=27744516986&partnerID=8YFLogxK

U2 - 10.1016/j.jns.2005.08.003

DO - 10.1016/j.jns.2005.08.003

M3 - Article

C2 - 16169561

AN - SCOPUS:27744516986

SN - 0022-510X

VL - 239

SP - 67

EP - 74

JO - Journal of the neurological sciences

JF - Journal of the neurological sciences

IS - 1

ER -

Benefits of high-dose, high-frequency interferon beta-1a in relapsing-remitting multiple sclerosis are sustained to 16 months: Final comparative results of the EVIDENCE trial

Abstract

Keywords

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this